Skip to main content
SpringerLink
Log in

A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma

An NCI Canada Clinical Trials Group study

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of VP-16 100 mg/m2 daily x 3 and cisplatin 25 mg/m2 daily x 3 in untreated patients with malignant mesothelioma. Twenty-seven eligible patients were entered on the trial and the majority had pleural and/or soft tissue disease. Myelosuppression and gastrointestinal symptoms were the most common toxicities, and were usually mild or moderate in severity. Only 3 partial responses were seen in the 26 patients evaluable (12%). We conclude that the combination of VP-16 and cisplatin when used in this fashion has only minimal activity in mesothelioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aisner J, Wiernik PH: Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8:335–343, 1981

    Google Scholar 

  2. Von Hoff DD, Elson D: Clinical results with cisplatin in lung cancer. In: Prestayko AW, Crooke S, Carter SK (eds), Cisplatin Current Status and New Developments. Vol. 1. Academic Press, New York, 1980, p 446

    Google Scholar 

  3. Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP: Cis-dichlorodiammineplatinum (II): Combination chemotherapy and cross resistance studies with tumors in mice. Cancer Treat Rep 63:1459–1473, 1979

    Google Scholar 

  4. Evans WK, Osoba D, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G: VP-16 and cisplatinum as first-line therapy for small cell lung cancer. J Clin Oncol 3:1471–1477, 1985

    Google Scholar 

  5. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316:1435–1440, 1987

    Google Scholar 

  6. Dabouis G, LeMevel B, Corroller J: Treatment of diffuse pleural malignant mesothelioma by Cis-dichlorodiammineplatinum (CDDP) in 9 patients. Cancer Chemother Pharmacol 5:209–210, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NCIC Clinical Trials Group, Kingston, Ontario, Canada

    Elizabeth A. Eisenhauer (Director)

  2. OCTRF Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada

    William K. Evans

  3. Cancer Control Agency of British Columbia, Vancouver, British Columbia, Canada

    Nevin Murray

  4. OCTRF London Regional Cancer Centre, London, Ontario, Canada

    Walter Kocha

  5. Nova Scotia Cancer Treatment Research Foundation, Halifax, Nova Scotia, Canada

    Rafal Wierzbicki

  6. Cancer Control Agency of British Columbia, Victoria, British Columbia, Canada

    Kenneth Wilson

Authors
  1. Elizabeth A. Eisenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William K. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nevin Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter Kocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafal Wierzbicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenhauer, E.A., Evans, W.K., Murray, N. et al. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. Invest New Drugs 6, 327–329 (1988). https://doi.org/10.1007/BF00173653

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173653

Key words

Search

Navigation